Research and Development

We are currently involved in new approaches to providing affordable, safe, and effective CAR T cell & biosimilar are a copy of a biological medical drug that is similar, but not identical, to the original biologic medical drug, The path to their approval is shorter as clinical trials and spend on research & development is much less than on the original biologic medical drug, thus fostering cheaper cost.

1.Development of automated large-scale manufacturing systems for 2nd and 3rd generation of CAR-Expressing T Cell & Vector

To make a new approach to provide affordable, safe, and effective anti human scFv sequences used for CAR T (Autologous & Allogeneic) Target anti human scFv are originated from LYSINE BIOTECH PRIVATE LIMITED

Read More About Products R&D Pipline

2.Lysine Biotech Product: Custom target selection for CAR-T therapy

Custom Target Identification and Selection

Custom high Affinity scFv Generation

Custom Synthetic construct CAR design for 2nd and 3rd generation of CAR-Expressing T Cell & Vector

Custom Synthetic construct 2nd and 3rd generation of lentiviral vector and packaging vector

Custom expression confirmation using different host systems like CHO-K1, HEK293, etc.,

Custom process development, scale-up, and validation

Validation of Technology & Tech transfer to client

Development of Diagnostic kits( ELISA and RAPID Test)

Isolation of the T-cell population from Human blood and transfection of HCAR-coding viral DNA into these cells at the manufacturing facility, transforming them into CAR-T cells

CAR-T In Vitro Assay and In Vivo Assay

patients are treated with modified T cells after administration of chemotherapy

3.Publications

I).Mayakrishnan Vijayakumar, BalakarthikeyanJanani, PriyaKannappan, Senthil Renganathan*, SameerAl-Ghamdi, Mohammed Alsaidan, Mohamed AAbdelaziz, Abubucker Peer Mohideen, Mohammad Shahid, Thiyagarajan Ramesh, 2021.In silico identification of potential inhibitors against main protease of SARS-CoV-2 6LU7 from Andrographis panniculata via molecular docking, binding energy calculations and molecular dynamics simulation studies Saudi Journal of Biological Sciences. Oct.29-2021. doi: 10.1016/j.sjbs.2021.10.060.

II).Renganathan Senthil*, Manokaran Sakthivel, Singaravelu Usha, 2021. Structure-based drug design of peroxisome proliferator-activated receptor gamma inhibitors: ferulic acid and derivatives. J Biomol Struct Dyn. 39(4):1295-1311.doi: 10.1080/07391102.2020.1740790.

III).Konda Mani Saravanan, Haiping Zhang, Renganathan Senthil*, Kevin Kumar Vijayakumar, Vignesh Sounderrajan, Yanjie Wei, Harshavardhan Shakila, 2020. Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds. J Biomol Struct Dyn. 1-9.doi: 10.1080/07391102.2020.1834457.

IV).Mahendrarajan Venkatramanan, Pitchaipillai Sankar Ganesh, Renganathan Senthil*, Jeyachandran Akshay, Arumugam Veera Ravi, Kulanthaivel Langeswaran, Jamuna Vadivelu, Samuthira Nagarajan, Kaliaperumal Rajendran, Esaki Muthu Shankar, 2020. Inhibition of Quorum Sensing and Biofilm Formation in Chromobacterium violaceum by Fruit Extracts of Passiflora edulis. ACS Omega.5(40):25605-25616.doi: 10.1021/acsomega.0c02483.

V).Subrata Pramanik, Manisha Thaker, Ananda Gopu Perumal*, Rajasekaran Ekambaram, Naresh Poondla, Markus Schmidt, Pok‐Son Kim, Arne Kutzner, Klaus Heese, 2020. Proteomic Atomics Reveals a Distinctive Uracil‐5‐Methyltransferase. Molecular Informatics. Vol. 39, Issue 5,doi:10.1002/minf.201900135 .